ESG3 Sept 2026, 05:10 pm
Senores Pharma Submits FY26 Business Responsibility and Sustainability Report
AI Summary
Senores Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI Listing Regulations. The report, also available on the company's website, details the company's operations, product/service offerings, and market presence. Senores Pharma, a B2B pharmaceutical developer and manufacturer, reported a turnover of INR 10,609 lakhs and a net worth of INR 74,990 lakhs for the fiscal year. Exports contributed 43.95% to the total turnover. The company operates on a standalone basis for its disclosures and has a grievance redressal mechanism in place for stakeholders.
Key Highlights
- Senores Pharma filed its FY26 BRSR as per SEBI regulations.
- Exports accounted for 43.95% of the company's total turnover.
- Company reported turnover of INR 10,609 lakhs and net worth of INR 74,990 lakhs.
- Disclosures are made on a standalone basis.
- Grievance redressal mechanism is operational for stakeholders.
Price Impact
More from SENORES